FHIR Implementation Guide for HCX
0.9.0 - CI Build
FHIR Implementation Guide for HCX
0.9.0 - CI Build
FHIR Implementation Guide for HCX - Local Development build (v0.9.0). See the Directory of published versions
<ValueSet xmlns="http://hl7.org/fhir">
<id value="informational-messages-codes"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>This value set contains 136 concepts</p><table class="codes"><tr><td style="white-space:nowrap"><b>Code</b></td><td><b>System</b></td><td><b>Display</b></td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MG045A"> </a> MG045A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Dialysis payable separately as an add on package</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MG072A"> </a> MG072A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Package cost of one session</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MG075A"> </a> MG075A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Rs. 5000 is the upper limit.
Can be booked at a lower rate also.
In fact the SHA should examine this package and confirm wheter the package has been booked at the usual market rate.
Can be booked for a pt. already admitted under any medical package.</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO014F"> </a> MO014F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant rectal cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO062A1"> </a> MO062A1</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>ACUTE LYMPHOBLASTIC LEUKEMIA</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MR001A"> </a> MR001A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SB030A"> </a> SB030A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be used for ORIF, wherever indicated.
Can not be used as an Add - on package</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SB032A"> </a> SB032A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis
Type V & VI to be taken up for Surgery straight away
In case Type I or II is booked a Pop Up to be shown "For Rockwood Type I & II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?"
For Hospitals booking Surgical Correction in Type I & Type II cases, Medical Audit will be conducted.</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SB032C"> </a> SB032C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis
Type V & VI to be taken up for Surgery straight away</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SB070A"> </a> SB070A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>LA for - K Wire & Screw
GA for - Nail & Plate</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SC076A"> </a> SC076A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>If the Hospital choses Pediatric Port in a pt. aged more than 14 years. Then it should be audited</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SE012A"> </a> SE012A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The package is inclusive of Eye Bank processing fee</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SE012B"> </a> SE012B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>This is a special follow up package, as in Corneal graft surgery, a follow up at 1 week is required.
At this time, the surgeon has to examine and then prescribe medicine for next one month.
The medicine for 1 month has to be given at the time of booking this package.
A signed reciept from the pt. is an essential document</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SE018A"> </a> SE018A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>To be done only after a prior scleral buckling surgery history</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SE022A"> </a> SE022A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 1 year of cataract surgery</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SE025A"> </a> SE025A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked as a complication of cataract surgery atleast 15 days after discharge</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SE029A"> </a> SE029A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The procedure is done only once per eye and not repeated</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SE029B"> </a> SE029B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>1. Claim to be raised after all 3 sittings have been done per eye.
2. The interval between subsequent sittings is atleast 1 week.</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SE033A"> </a> SE033A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Pre-auth to be raised only in cases which have a prior history of Vitreoretinal surgery done atleast 3 months ago</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SG097A"> </a> SG097A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 15 days of Ileostomy and then every 2 months thereafter till the closure of stoma.
The Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: Ileostomy - bags, adhesive, clips etc for 2 months</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SG097B"> </a> SG097B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Can be booked only after 15 days of Colostomy and then every 2 months thereafter till the closure of stoma.
The Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: colostomy - bags, adhesive, clips etc for 2 months</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SU052A"> </a> SU052A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Payment to be made after completion of one month.</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SU060A"> </a> SU060A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Claim to be raised after 6th Cycle</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SU060B"> </a> SU060B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Claim for Rs. 15,000 can be raised after 6th Cycle.
Remainaing Rs. 15,000 can be claimed after 12th Cycle</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SU071C"> </a> SU071C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>No payment to be done to the Hospital for this stage
The package can be booked only if the first stage package has been booked prior to this</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SU071D"> </a> SU071D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>The package can be booked only if the first stage and / or intermediate stage package has been booked prior to this</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-SV032A"> </a> SV032A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Associated with CABG
Need to submit Barcode/ ID number of IABP. Intra-operative use of IABP as a part of operative strategy, not included
Incidence - 5% to 7%
Scrutiny of Hospitals where incidence is more than twice of prescribed limit</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001A"> </a> MO001A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer
Metastatic breast cancer
(should not have received the same regimen or AC earlier)</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001B"> </a> MO001B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy after 4 cycles of AC or EC</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001C"> </a> MO001C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metstatic breast cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001D"> </a> MO001D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy
Metstatic breast cancer
(should not have received the same regimen earlier)</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001E"> </a> MO001E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy and high nodal burden
Metastatic breast cancer
(should not have received the same regimen earlier)</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001F"> </a> MO001F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer with Her-2 neu positive patients</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001G"> </a> MO001G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer
ER / PR positive metastatic breast cancer
(if not receive earlier)</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001H"> </a> MO001H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer
ER / PR positive metastatic breast cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001I"> </a> MO001I</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy breast cancer
metastatic breast cancer
(if not received earlier)</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001L"> </a> MO001L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy in breast cancer
Metstatic breast cancer
(should not have received the same regimen or EC earlier)</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001M"> </a> MO001M</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic breast cancer ER / PR positive</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001N"> </a> MO001N</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant or neoadjuvant therapy breast cancer
metastatic breast cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO001O"> </a> MO001O</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic breast cancer ER / PR positive</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO002A"> </a> MO002A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic bone malignancy and multiple myeloma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO003A"> </a> MO003A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic ovarian adenocarcinoma second line</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO003B"> </a> MO003B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO004A"> </a> MO004A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Testicular Seminoma, Adjuvant</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO004B"> </a> MO004B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO004D"> </a> MO004D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Germ cell tumour second line therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO005A"> </a> MO005A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>First line therapy for high - risk Gestational Trophoblastic Neoplasia
Second line</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO005C"> </a> MO005C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>First line therapy for low risk Gestational Trophoblastic Neoplasia</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO006A"> </a> MO006A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and metastatic Cervical Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO006B"> </a> MO006B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and Stage III cervical cancer definitive therapy along with Radiation therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO007A"> </a> MO007A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant and Metastatic Endometrial Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO007B"> </a> MO007B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Endometrial Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO008A"> </a> MO008A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>NACT, mets</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO008B"> </a> MO008B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and Stage III cervical cancer definitive therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO009A"> </a> MO009A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Ewing Sarcoma second line chemotherapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO010A"> </a> MO010A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma Neoadjuvant and adjuvant therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO010B"> </a> MO010B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Osteogenic Sarcoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO010C"> </a> MO010C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma Neoadjuvant therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO010D"> </a> MO010D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Osteogenic carcinoma adjuvant therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO011A"> </a> MO011A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>NACT, Adjuvant, mets (if cardiac dysfunction)</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO011B"> </a> MO011B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Soft tissue sarcoma neoadjuvant, adjuvant and metastatic</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO012A"> </a> MO012A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Melanoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO013A"> </a> MO013A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Stage II and III anal Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO013C"> </a> MO013C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Anal Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO014A"> </a> MO014A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and Metastatic Colorectal Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO014B"> </a> MO014B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Colorectal Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO014H"> </a> MO014H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant Colorectal Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO015A"> </a> MO015A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant esophageal cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO015B"> </a> MO015B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Upper esophageal neoadjuvant and with RT as adjuvant</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO015D"> </a> MO015D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>With RT in definitive non-metastatic</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO015E"> </a> MO015E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic without RT</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO016B"> </a> MO016B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic second line esophageal and stomach cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO016C"> </a> MO016C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends
Lower esophageal and stomach Cancer with RT as adjuvant</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO016D"> </a> MO016D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till completion of RT
Lower esophageal and stomach Cancer with RT as adjuvant</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO016E"> </a> MO016E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and Metastatic Stomach, Lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO016F"> </a> MO016F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO016J"> </a> MO016J</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metatstaic lower esophageal and stomach Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO016K"> </a> MO016K</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant for stomach and lower esophageal (adenocarcinoma) cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO016L"> </a> MO016L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant, along with Radiation (concurrent), metastatic esophageal cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO017A"> </a> MO017A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Liver confined hepatocellular carcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO017B"> </a> MO017B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Meatastatic hepatocellular carcinoma (except child Pugh c)
Liver confined but not suitable for liver directed therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO018B"> </a> MO018B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic pancreatic cancer - first line</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO018C"> </a> MO018C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and adjuvant locally advanced pancreatic cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO018E"> </a> MO018E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends
Neoadjuvant and adjuvant locally advanced pancreatic cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO018F"> </a> MO018F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Pancreatic cancer - adjuvant</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO019A"> </a> MO019A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant and metastatic gall bladder and cholnagicarcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO019B"> </a> MO019B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic pancreatic cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO019C"> </a> MO019C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic gall bladder and cholngiocarcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO019D"> </a> MO019D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Till RT ends
Definitive and Adjuvant therapy in gall bladder cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO019E"> </a> MO019E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metatstatic Gall Bladder Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO020A"> </a> MO020A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic GIST</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO020B"> </a> MO020B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic GIST</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO021A"> </a> MO021A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Adjuvant therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO022A"> </a> MO022A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic mesothelioma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO022B"> </a> MO022B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant,adjuvant and metastatic mesothelioma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO023A"> </a> MO023A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant Chemotherapy and metastatic thymic carcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024A"> </a> MO024A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and metastatic head and neck squamou cell cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024B"> </a> MO024B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Definitive therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024C"> </a> MO024C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024D"> </a> MO024D</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Metastatic squamou cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024E"> </a> MO024E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamou cell head and neck cancer, salivary gland cancers</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024F"> </a> MO024F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Head and neck squamous cell carcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024G"> </a> MO024G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024L"> </a> MO024L</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, salivary gland cancers, nasopharyngeal carcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO024M"> </a> MO024M</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic squamous cell head and neck cancer, salivary gland cancers</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO025A"> </a> MO025A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic renal cell carcinoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO026A"> </a> MO026A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Metastatic urothelial cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO026B"> </a> MO026B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant, Metastatic urothelial cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO026F"> </a> MO026F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic urothelial cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO027A"> </a> MO027A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant, Metastatic penile cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO027C"> </a> MO027C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Penile Cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO028A"> </a> MO028A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic prostate cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO033A"> </a> MO033A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Multiagent chemotherapy variable in each protocol</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO047C"> </a> MO047C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Optional Vincristine and Prednsiolone
Intrathecal Methotrexate</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO048C"> </a> MO048C</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Optional Vincristine and Prednsiolone, intrathecal Methotrexate</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO054A"> </a> MO054A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Histiocytosis Protocol - Induction</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO054B"> </a> MO054B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Histiocytosis Protocol - Maintenance</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO055A"> </a> MO055A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Low Grade Glioma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO056A"> </a> MO056A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Medulloblastoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO057A"> </a> MO057A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neuroblastoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO058A"> </a> MO058A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Retinoblastoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO059A"> </a> MO059A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Rhabdomyosarcoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO060A"> </a> MO060A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Rhabdomyosarcoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO062A"> </a> MO062A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Phase II, CNS Therapy Reinduction</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO066A"> </a> MO066A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Relapsed Hodgkins Lymphoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO066B"> </a> MO066B</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Hodgkins Lymphoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO068A"> </a> MO068A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Non - Hodgkins Lymphoma</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071A"> </a> MO071A</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metstatic non small cell lung cancer - second line</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071E"> </a> MO071E</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic non small cell lung (adenocarcinoma) cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071F"> </a> MO071F</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic small cell lung cancer - second line</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071G"> </a> MO071G</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071H"> </a> MO071H</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071K"> </a> MO071K</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant and Metastatic Non Small Cell Lung cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071O"> </a> MO071O</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Concurrent chemoradiation in Non Small Cell lung cancer</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071Q"> </a> MO071Q</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung cancer (adnocarcinoma and adenosquamous carcinoma)</td></tr><tr><td style="white-space:nowrap"><a name="http---hcxprotocol.io-codes-informational-messages-codes-MO071R"> </a> MO071R</td><td>http://hcxprotocol.io/codes/informational-messages-codes</td><td>Metastatic non small cell lung cancer (adenocarcinoma) as maintenance after
Carboplatin + Pemetrexed and
Cisplatin + Pemetrexed 4 -6 cycles</td></tr></table></div>
</text>
<url
value="https://ig.hcxprotocol.io/v0.9/ValueSet-informational-messages-codes.html"/>
<version value="0.9.0"/>
<name value="InformationalMessagesCodes"/>
<status value="active"/>
<date value="2022-06-01"/>
<publisher value="HCX Open Community"/>
<contact>
<name value="HCX Open Community"/>
<telecom>
<system value="url"/>
<value value="http://hcxprotocol.io/"/>
</telecom>
</contact>
<description
value="This is the value set that includes the informational messages codes"/>
<expansion>
<timestamp value="2022-06-01T08:15:30+05:30"/>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MG045A"/>
<display value="Dialysis payable separately as an add on package"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MG072A"/>
<display value="Package cost of one session"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MG075A"/>
<display
value="Rs. 5000 is the upper limit.
Can be booked at a lower rate also.
In fact the SHA should examine this package and confirm wheter the package has been booked at the usual market rate.
Can be booked for a pt. already admitted under any medical package."/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO014F"/>
<display value="Neoadjuvant and adjuvant rectal cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO062A1"/>
<display value="ACUTE LYMPHOBLASTIC LEUKEMIA"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MR001A"/>
<display
value="The Procedure will cover ALL, Hodgkin's Lymphoma, Wilm's Tumour, NHL, Retinoblastoma & certain Bone Tumours`"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SB030A"/>
<display
value="Can be used for ORIF, wherever indicated.
Can not be used as an Add - on package"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SB032A"/>
<display
value="Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis
Type V & VI to be taken up for Surgery straight away
In case Type I or II is booked a Pop Up to be shown "For Rockwood Type I & II - AC Joint injury, experts recommend Medical Management, are you sure you want to do Surgical Correction in this case ?"
For Hospitals booking Surgical Correction in Type I & Type II cases, Medical Audit will be conducted."/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SB032C"/>
<display
value="Surgical Management for Type III & IV Rockwood to be decided by the surgeon on case to case basis
Type V & VI to be taken up for Surgery straight away"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SB070A"/>
<display value="LA for - K Wire & Screw
GA for - Nail & Plate"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SC076A"/>
<display
value="If the Hospital choses Pediatric Port in a pt. aged more than 14 years. Then it should be audited"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SE012A"/>
<display value="The package is inclusive of Eye Bank processing fee"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SE012B"/>
<display
value="This is a special follow up package, as in Corneal graft surgery, a follow up at 1 week is required.
At this time, the surgeon has to examine and then prescribe medicine for next one month.
The medicine for 1 month has to be given at the time of booking this package.
A signed reciept from the pt. is an essential document"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SE018A"/>
<display
value="To be done only after a prior scleral buckling surgery history"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SE022A"/>
<display value="Can be booked only after 1 year of cataract surgery"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SE025A"/>
<display
value="Can be booked as a complication of cataract surgery atleast 15 days after discharge"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SE029A"/>
<display
value="The procedure is done only once per eye and not repeated"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SE029B"/>
<display
value="1. Claim to be raised after all 3 sittings have been done per eye.
2. The interval between subsequent sittings is atleast 1 week."/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SE033A"/>
<display
value="Pre-auth to be raised only in cases which have a prior history of Vitreoretinal surgery done atleast 3 months ago"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SG097A"/>
<display
value="Can be booked only after 15 days of Ileostomy and then every 2 months thereafter till the closure of stoma.
The Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: Ileostomy - bags, adhesive, clips etc for 2 months"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SG097B"/>
<display
value="Can be booked only after 15 days of Colostomy and then every 2 months thereafter till the closure of stoma.
The Hospital has to upload a signed statement from pt. that s/he has received the cosnumables: colostomy - bags, adhesive, clips etc for 2 months"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SU052A"/>
<display value="Payment to be made after completion of one month."/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SU060A"/>
<display value="Claim to be raised after 6th Cycle"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SU060B"/>
<display
value="Claim for Rs. 15,000 can be raised after 6th Cycle.
Remainaing Rs. 15,000 can be claimed after 12th Cycle"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SU071C"/>
<display
value="No payment to be done to the Hospital for this stage
The package can be booked only if the first stage package has been booked prior to this"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SU071D"/>
<display
value="The package can be booked only if the first stage and / or intermediate stage package has been booked prior to this"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="SV032A"/>
<display
value="Associated with CABG
Need to submit Barcode/ ID number of IABP. Intra-operative use of IABP as a part of operative strategy, not included
Incidence - 5% to 7%
Scrutiny of Hospitals where incidence is more than twice of prescribed limit"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001A"/>
<display
value="Adjuvant therapy in breast cancer
Metastatic breast cancer
(should not have received the same regimen or AC earlier)"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001B"/>
<display value="Adjuvant therapy after 4 cycles of AC or EC"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001C"/>
<display value="Metstatic breast cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001D"/>
<display
value="Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy
Metstatic breast cancer
(should not have received the same regimen earlier)"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001E"/>
<display
value="Adjuvant therapy in breast cancer with cardiac dysfunction or not suitable for anthracycline based therapy and high nodal burden
Metastatic breast cancer
(should not have received the same regimen earlier)"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001F"/>
<display
value="Adjuvant therapy in breast cancer with Her-2 neu positive patients"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001G"/>
<display
value="Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer
ER / PR positive metastatic breast cancer
(if not receive earlier)"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001H"/>
<display
value="Adjuvant or neoadjuvant therapy in ER / PR psotive breast cancer
ER / PR positive metastatic breast cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001I"/>
<display
value="Adjuvant or neoadjuvant therapy breast cancer
metastatic breast cancer
(if not received earlier)"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001L"/>
<display
value="Adjuvant therapy in breast cancer
Metstatic breast cancer
(should not have received the same regimen or EC earlier)"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001M"/>
<display value="Metastatic breast cancer ER / PR positive"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001N"/>
<display
value="Adjuvant or neoadjuvant therapy breast cancer
metastatic breast cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO001O"/>
<display value="Metastatic breast cancer ER / PR positive"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO002A"/>
<display value="Metastatic bone malignancy and multiple myeloma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO003A"/>
<display value="Metastatic ovarian adenocarcinoma second line"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO003B"/>
<display
value="Neoadjuvant, adjuvant and metastatic ovarian adenocarcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO004A"/>
<display value="Testicular Seminoma, Adjuvant"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO004B"/>
<display
value="Germ cell tumour of any site for Neoadjuvant, adjuvant or metastatic first line"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO004D"/>
<display value="Germ cell tumour second line therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO005A"/>
<display
value="First line therapy for high - risk Gestational Trophoblastic Neoplasia
Second line"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO005C"/>
<display
value="First line therapy for low risk Gestational Trophoblastic Neoplasia"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO006A"/>
<display value="Neoadjuvant and metastatic Cervical Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO006B"/>
<display
value="Stage II and Stage III cervical cancer definitive therapy along with Radiation therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO007A"/>
<display
value="Neoadjuvant, Adjuvant and Metastatic Endometrial Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO007B"/>
<display value="Metastatic Endometrial Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO008A"/>
<display value="NACT, mets"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO008B"/>
<display
value="Stage II and Stage III cervical cancer definitive therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO009A"/>
<display value="Ewing Sarcoma second line chemotherapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO010A"/>
<display value="Osteogenic carcinoma Neoadjuvant and adjuvant therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO010B"/>
<display value="Relapsed Osteogenic Sarcoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO010C"/>
<display value="Osteogenic carcinoma Neoadjuvant therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO010D"/>
<display value="Osteogenic carcinoma adjuvant therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO011A"/>
<display value="NACT, Adjuvant, mets (if cardiac dysfunction)"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO011B"/>
<display
value="Soft tissue sarcoma neoadjuvant, adjuvant and metastatic"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO012A"/>
<display value="Metastatic Melanoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO013A"/>
<display value="Stage II and III anal Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO013C"/>
<display value="Metastatic Anal Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO014A"/>
<display value="Adjuvant and Metastatic Colorectal Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO014B"/>
<display value="Metastatic Colorectal Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO014H"/>
<display value="Neoadjuvant and adjuvant Colorectal Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO015A"/>
<display value="Neoadjuvant and adjuvant esophageal cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO015B"/>
<display
value="Upper esophageal neoadjuvant and with RT as adjuvant"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO015D"/>
<display value="With RT in definitive non-metastatic"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO015E"/>
<display value="Metastatic without RT"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO016B"/>
<display value="Metastatic second line esophageal and stomach cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO016C"/>
<display
value="Till RT ends
Lower esophageal and stomach Cancer with RT as adjuvant"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO016D"/>
<display
value="Till completion of RT
Lower esophageal and stomach Cancer with RT as adjuvant"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO016E"/>
<display
value="Adjuvant and Metastatic Stomach, Lower esophageal (adenocarcinoma) cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO016F"/>
<display
value="Neoadjuvant, adjuvant and metastatic stomach and lower esophageal (adenocarcinoma) cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO016J"/>
<display value="Metatstaic lower esophageal and stomach Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO016K"/>
<display
value="Adjuvant for stomach and lower esophageal (adenocarcinoma) cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO016L"/>
<display
value="Neoadjuvant, adjuvant, along with Radiation (concurrent), metastatic esophageal cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO017A"/>
<display value="Liver confined hepatocellular carcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO017B"/>
<display
value="Meatastatic hepatocellular carcinoma (except child Pugh c)
Liver confined but not suitable for liver directed therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO018B"/>
<display value="Metastatic pancreatic cancer - first line"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO018C"/>
<display
value="Neoadjuvant and adjuvant locally advanced pancreatic cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO018E"/>
<display
value="Till RT ends
Neoadjuvant and adjuvant locally advanced pancreatic cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO018F"/>
<display value="Pancreatic cancer - adjuvant"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO019A"/>
<display
value="Adjuvant and metastatic gall bladder and cholnagicarcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO019B"/>
<display
value="Neoadjuvant, adjuvant and metastatic pancreatic cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO019C"/>
<display value="Metastatic gall bladder and cholngiocarcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO019D"/>
<display
value="Till RT ends
Definitive and Adjuvant therapy in gall bladder cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO019E"/>
<display value="Metatstatic Gall Bladder Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO020A"/>
<display value="Neoadjuvant, adjuvant and metastatic GIST"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO020B"/>
<display value="Metastatic GIST"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO021A"/>
<display value="Adjuvant therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO022A"/>
<display value="Metastatic mesothelioma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO022B"/>
<display value="Neoadjuvant,adjuvant and metastatic mesothelioma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO023A"/>
<display
value="Neoadjuvant Chemotherapy and metastatic thymic carcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024A"/>
<display
value="Neoadjuvant and metastatic head and neck squamou cell cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024B"/>
<display value="Definitive therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024C"/>
<display
value="Metastatic squamous cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024D"/>
<display
value="Neoadjuvant, Metastatic squamou cell head and neck cancer, nasopharyngeal cancer, salivary gland cancers"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024E"/>
<display
value="Metastatic squamou cell head and neck cancer, salivary gland cancers"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024F"/>
<display value="Metastatic Head and neck squamous cell carcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024G"/>
<display
value="Neoadjuvant, adjuvant and metastatic esthesioneuroblastoma and Neuroendocrine carcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024L"/>
<display
value="Metastatic squamous cell head and neck cancer, salivary gland cancers, nasopharyngeal carcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO024M"/>
<display
value="Metastatic squamous cell head and neck cancer, salivary gland cancers"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO025A"/>
<display value="Metastatic renal cell carcinoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO026A"/>
<display value="Neoadjuvant, Metastatic urothelial cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO026B"/>
<display value="Neoadjuvant, Adjuvant, Metastatic urothelial cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO026F"/>
<display value="Metastatic urothelial cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO027A"/>
<display value="Neoadjuvant, Adjuvant, Metastatic penile cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO027C"/>
<display value="Metastatic Penile Cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO028A"/>
<display value="Metastatic prostate cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO033A"/>
<display value="Multiagent chemotherapy variable in each protocol"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO047C"/>
<display
value="Optional Vincristine and Prednsiolone
Intrathecal Methotrexate"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO048C"/>
<display
value="Optional Vincristine and Prednsiolone, intrathecal Methotrexate"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO054A"/>
<display value="Histiocytosis Protocol - Induction"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO054B"/>
<display value="Histiocytosis Protocol - Maintenance"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO055A"/>
<display value="Low Grade Glioma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO056A"/>
<display value="Medulloblastoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO057A"/>
<display value="Neuroblastoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO058A"/>
<display value="Retinoblastoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO059A"/>
<display value="Rhabdomyosarcoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO060A"/>
<display value="Relapsed Rhabdomyosarcoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO062A"/>
<display value="Phase II, CNS Therapy Reinduction"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO066A"/>
<display value="Relapsed Hodgkins Lymphoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO066B"/>
<display value="Hodgkins Lymphoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO068A"/>
<display value="Non - Hodgkins Lymphoma"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071A"/>
<display value="Metstatic non small cell lung cancer - second line"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071E"/>
<display
value="Metastatic non small cell lung (adenocarcinoma) cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071F"/>
<display value="Metastatic small cell lung cancer - second line"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071G"/>
<display
value="Metastatic Non Small Cell Lung Cancer - in patients unfit for combination therapy"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071H"/>
<display
value="Neoadjuvant, concurrent with radiation and metastaic small cell lung cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071K"/>
<display value="Neoadjuvant and Metastatic Non Small Cell Lung cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071O"/>
<display
value="Concurrent chemoradiation in Non Small Cell lung cancer"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071Q"/>
<display
value="Neoadjuvant, Adjuvant and Metastatic Non Small Cell Lung cancer (adnocarcinoma and adenosquamous carcinoma)"/>
</contains>
<contains>
<system
value="http://hcxprotocol.io/codes/informational-messages-codes"/>
<code value="MO071R"/>
<display
value="Metastatic non small cell lung cancer (adenocarcinoma) as maintenance after
Carboplatin + Pemetrexed and
Cisplatin + Pemetrexed 4 -6 cycles"/>
</contains>
</expansion>
</ValueSet>
IG © 2021+ HCX Open Community. Package hcxprotocol.io#0.9.0 based on FHIR 4.0.1. Generated 2023-12-14
Links: Table of Contents |
QA Report